| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 179 | 2024 | 1003 | 16.360 |
Why?
|
| Antirheumatic Agents | 91 | 2024 | 255 | 11.730 |
Why?
|
| Methotrexate | 53 | 2024 | 228 | 4.980 |
Why?
|
| Receptors, Tumor Necrosis Factor | 34 | 2013 | 140 | 3.680 |
Why?
|
| Immunoglobulin G | 31 | 2017 | 782 | 2.600 |
Why?
|
| Granulomatosis with Polyangiitis | 16 | 2023 | 42 | 2.540 |
Why?
|
| Rheumatology | 15 | 2023 | 89 | 2.510 |
Why?
|
| Peptides, Cyclic | 10 | 2017 | 262 | 2.290 |
Why?
|
| Antibodies, Monoclonal | 29 | 2016 | 1264 | 2.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 25 | 2024 | 1137 | 2.240 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 10 | 2023 | 20 | 1.870 |
Why?
|
| Autoantibodies | 12 | 2022 | 1362 | 1.700 |
Why?
|
| Immunoconjugates | 10 | 2013 | 87 | 1.630 |
Why?
|
| Giant Cell Arteritis | 10 | 2023 | 48 | 1.580 |
Why?
|
| Etanercept | 33 | 2022 | 51 | 1.560 |
Why?
|
| Microscopic Polyangiitis | 8 | 2023 | 12 | 1.550 |
Why?
|
| Rheumatoid Factor | 9 | 2024 | 157 | 1.340 |
Why?
|
| Middle Aged | 163 | 2024 | 27078 | 1.260 |
Why?
|
| Rheumatic Diseases | 7 | 2020 | 49 | 1.190 |
Why?
|
| Humans | 278 | 2024 | 115859 | 1.180 |
Why?
|
| Churg-Strauss Syndrome | 6 | 2023 | 17 | 1.140 |
Why?
|
| Takayasu Arteritis | 6 | 2023 | 8 | 1.130 |
Why?
|
| Double-Blind Method | 50 | 2017 | 1664 | 1.100 |
Why?
|
| Osteoarthritis | 7 | 2023 | 173 | 1.060 |
Why?
|
| Severity of Illness Index | 52 | 2022 | 2590 | 1.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 18 | 2009 | 301 | 1.020 |
Why?
|
| Drug Therapy, Combination | 33 | 2024 | 962 | 1.010 |
Why?
|
| Coronary Disease | 3 | 2017 | 348 | 1.000 |
Why?
|
| Aged | 104 | 2023 | 19292 | 0.970 |
Why?
|
| Women's Health | 7 | 2018 | 272 | 0.960 |
Why?
|
| Osteoarthritis, Knee | 11 | 2023 | 213 | 0.950 |
Why?
|
| Female | 175 | 2024 | 60070 | 0.920 |
Why?
|
| Genetic Predisposition to Disease | 18 | 2023 | 2201 | 0.900 |
Why?
|
| Scleroderma, Systemic | 15 | 2017 | 97 | 0.890 |
Why?
|
| Biological Products | 4 | 2022 | 172 | 0.880 |
Why?
|
| Treatment Outcome | 75 | 2024 | 9163 | 0.880 |
Why?
|
| Cardiovascular Diseases | 4 | 2018 | 1724 | 0.860 |
Why?
|
| Male | 166 | 2024 | 56103 | 0.830 |
Why?
|
| Synovial Membrane | 7 | 2024 | 74 | 0.800 |
Why?
|
| Abatacept | 13 | 2021 | 40 | 0.800 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2022 | 25 | 0.790 |
Why?
|
| Biomarkers | 18 | 2022 | 3474 | 0.780 |
Why?
|
| Polymorphism, Single Nucleotide | 22 | 2021 | 2004 | 0.780 |
Why?
|
| Atherosclerosis | 3 | 2019 | 341 | 0.770 |
Why?
|
| Adult | 114 | 2023 | 30814 | 0.750 |
Why?
|
| Arthroplasty, Replacement, Knee | 4 | 2023 | 246 | 0.690 |
Why?
|
| Cytokines | 9 | 2023 | 1858 | 0.680 |
Why?
|
| Postmenopause | 4 | 2017 | 301 | 0.670 |
Why?
|
| Joint Diseases | 1 | 2019 | 59 | 0.640 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 9 | 2023 | 33 | 0.630 |
Why?
|
| C-Reactive Protein | 6 | 2016 | 364 | 0.610 |
Why?
|
| Immunosuppressive Agents | 9 | 2023 | 666 | 0.610 |
Why?
|
| Infliximab | 12 | 2022 | 94 | 0.590 |
Why?
|
| Recombinant Fusion Proteins | 8 | 2006 | 617 | 0.590 |
Why?
|
| T-Lymphocytes | 10 | 2023 | 1758 | 0.590 |
Why?
|
| Stroke | 2 | 2016 | 1016 | 0.580 |
Why?
|
| Immunologic Factors | 3 | 2014 | 219 | 0.570 |
Why?
|
| Adalimumab | 8 | 2022 | 44 | 0.560 |
Why?
|
| Antigens, CD | 8 | 2020 | 443 | 0.560 |
Why?
|
| Serum Amyloid A Protein | 1 | 2016 | 29 | 0.550 |
Why?
|
| HLA Antigens | 1 | 2017 | 224 | 0.530 |
Why?
|
| Surgeons | 3 | 2023 | 238 | 0.510 |
Why?
|
| Inflammation | 9 | 2023 | 2502 | 0.500 |
Why?
|
| Health Status | 20 | 2016 | 727 | 0.480 |
Why?
|
| Hydroxychloroquine | 9 | 2017 | 55 | 0.470 |
Why?
|
| Genome-Wide Association Study | 9 | 2021 | 1277 | 0.470 |
Why?
|
| CD4 Antigens | 6 | 1998 | 124 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2024 | 1217 | 0.450 |
Why?
|
| Osteoarthritis, Hip | 2 | 2023 | 40 | 0.440 |
Why?
|
| Risk Factors | 15 | 2023 | 8715 | 0.430 |
Why?
|
| Gout | 3 | 2008 | 37 | 0.430 |
Why?
|
| Dose-Response Relationship, Drug | 22 | 2009 | 1871 | 0.410 |
Why?
|
| Lymphocyte Activation | 9 | 2006 | 1056 | 0.410 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2019 | 447 | 0.400 |
Why?
|
| Sulfasalazine | 7 | 2017 | 21 | 0.390 |
Why?
|
| Clinical Trials as Topic | 14 | 2010 | 944 | 0.390 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 4 | 2000 | 310 | 0.390 |
Why?
|
| Longitudinal Studies | 14 | 2022 | 2416 | 0.390 |
Why?
|
| Pain Measurement | 13 | 2019 | 449 | 0.380 |
Why?
|
| Recombinant Proteins | 12 | 2020 | 1244 | 0.380 |
Why?
|
| Vaccination | 5 | 2020 | 1209 | 0.370 |
Why?
|
| Disability Evaluation | 10 | 2019 | 271 | 0.370 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2016 | 666 | 0.360 |
Why?
|
| Alleles | 10 | 2017 | 817 | 0.360 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2010 | 69 | 0.360 |
Why?
|
| Pain | 9 | 2023 | 712 | 0.350 |
Why?
|
| Biological Factors | 2 | 2022 | 37 | 0.350 |
Why?
|
| B-Lymphocytes | 7 | 2023 | 771 | 0.350 |
Why?
|
| Prospective Studies | 20 | 2023 | 6276 | 0.350 |
Why?
|
| Drug Administration Schedule | 10 | 2012 | 724 | 0.340 |
Why?
|
| Radiography | 15 | 2015 | 826 | 0.340 |
Why?
|
| Patient Selection | 6 | 2017 | 655 | 0.320 |
Why?
|
| Polyethylene Glycols | 2 | 2010 | 576 | 0.320 |
Why?
|
| Cyclooxygenase Inhibitors | 4 | 2003 | 72 | 0.320 |
Why?
|
| Aged, 80 and over | 21 | 2023 | 6434 | 0.310 |
Why?
|
| Cohort Studies | 13 | 2021 | 4960 | 0.300 |
Why?
|
| Smoking | 5 | 2015 | 1465 | 0.300 |
Why?
|
| Vasculitis | 3 | 2015 | 71 | 0.290 |
Why?
|
| Interferon-alpha | 2 | 2021 | 187 | 0.290 |
Why?
|
| Arthritis, Psoriatic | 1 | 2007 | 16 | 0.290 |
Why?
|
| Contraception | 2 | 2019 | 118 | 0.290 |
Why?
|
| Fatigue | 3 | 2019 | 296 | 0.280 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 250 | 0.280 |
Why?
|
| Polyarteritis Nodosa | 2 | 2021 | 7 | 0.280 |
Why?
|
| Incidence | 7 | 2020 | 2336 | 0.280 |
Why?
|
| Arthritis | 4 | 2003 | 110 | 0.280 |
Why?
|
| Genetic Pleiotropy | 2 | 2019 | 30 | 0.280 |
Why?
|
| United States | 19 | 2023 | 12319 | 0.280 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2006 | 65 | 0.280 |
Why?
|
| Interleukin-2 | 3 | 1996 | 416 | 0.270 |
Why?
|
| Arthritis, Reactive | 3 | 1996 | 8 | 0.270 |
Why?
|
| Diphtheria Toxin | 2 | 1996 | 51 | 0.270 |
Why?
|
| Predictive Value of Tests | 8 | 2017 | 1813 | 0.270 |
Why?
|
| Epitopes | 5 | 2017 | 438 | 0.270 |
Why?
|
| Gout Suppressants | 1 | 2005 | 20 | 0.260 |
Why?
|
| Hyperuricemia | 1 | 2005 | 43 | 0.260 |
Why?
|
| Xanthine Oxidase | 1 | 2005 | 72 | 0.260 |
Why?
|
| Thiazoles | 1 | 2005 | 110 | 0.250 |
Why?
|
| Neoplasms | 2 | 2017 | 2114 | 0.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 1995 | 967 | 0.250 |
Why?
|
| Hyperostosis, Diffuse Idiopathic Skeletal | 1 | 2004 | 4 | 0.250 |
Why?
|
| Peroxidase | 4 | 2019 | 157 | 0.250 |
Why?
|
| Interleukins | 1 | 2006 | 237 | 0.240 |
Why?
|
| Penicillamine | 6 | 2006 | 22 | 0.240 |
Why?
|
| Immunoglobulin Fc Fragments | 2 | 2002 | 35 | 0.240 |
Why?
|
| Blood Sedimentation | 6 | 2016 | 34 | 0.240 |
Why?
|
| Administration, Oral | 6 | 2012 | 733 | 0.240 |
Why?
|
| Time Factors | 15 | 2018 | 6182 | 0.230 |
Why?
|
| Remission Induction | 6 | 2023 | 240 | 0.230 |
Why?
|
| Immunotherapy | 4 | 1996 | 481 | 0.230 |
Why?
|
| Genetic Association Studies | 4 | 2015 | 352 | 0.230 |
Why?
|
| Rheumatologists | 1 | 2023 | 12 | 0.230 |
Why?
|
| Relaxin | 4 | 2009 | 15 | 0.230 |
Why?
|
| Hyaluronic Acid | 2 | 2003 | 190 | 0.230 |
Why?
|
| Social Class | 2 | 2016 | 210 | 0.230 |
Why?
|
| Cervical Vertebrae | 1 | 2004 | 104 | 0.230 |
Why?
|
| Myeloblastin | 3 | 2019 | 9 | 0.220 |
Why?
|
| Spinal Stenosis | 2 | 1996 | 24 | 0.220 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 4443 | 0.220 |
Why?
|
| Scleritis | 1 | 2023 | 18 | 0.220 |
Why?
|
| Rituximab | 2 | 2023 | 149 | 0.220 |
Why?
|
| Deglutition Disorders | 1 | 2004 | 119 | 0.220 |
Why?
|
| Thrombospondin 1 | 1 | 2023 | 19 | 0.220 |
Why?
|
| Registries | 4 | 2015 | 1772 | 0.220 |
Why?
|
| Azathioprine | 1 | 2023 | 50 | 0.220 |
Why?
|
| Meniscus | 1 | 2023 | 21 | 0.210 |
Why?
|
| Extracellular Traps | 1 | 2023 | 40 | 0.210 |
Why?
|
| Injections, Subcutaneous | 6 | 2009 | 137 | 0.210 |
Why?
|
| HLA-DRB1 Chains | 6 | 2014 | 99 | 0.210 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 79 | 0.200 |
Why?
|
| Synovial Fluid | 4 | 2017 | 57 | 0.200 |
Why?
|
| Uncertainty | 1 | 2022 | 97 | 0.200 |
Why?
|
| Self Report | 3 | 2016 | 700 | 0.200 |
Why?
|
| Leukocyte Count | 4 | 2015 | 295 | 0.200 |
Why?
|
| Hypothyroidism | 1 | 2022 | 65 | 0.200 |
Why?
|
| Computed Tomography Angiography | 2 | 2020 | 105 | 0.200 |
Why?
|
| Subclavian Artery | 2 | 2020 | 29 | 0.200 |
Why?
|
| Case-Control Studies | 10 | 2023 | 3054 | 0.200 |
Why?
|
| Flow Cytometry | 5 | 2019 | 1060 | 0.200 |
Why?
|
| Interleukin-11 | 1 | 2001 | 9 | 0.190 |
Why?
|
| Osteoporosis | 3 | 2010 | 227 | 0.190 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 2023 | 131 | 0.190 |
Why?
|
| Adenosine Deaminase | 1 | 2021 | 26 | 0.190 |
Why?
|
| Kidney Diseases | 4 | 2020 | 355 | 0.190 |
Why?
|
| Synoviocytes | 1 | 2020 | 10 | 0.190 |
Why?
|
| HLA-DR Antigens | 5 | 2010 | 220 | 0.190 |
Why?
|
| STAT1 Transcription Factor | 1 | 2021 | 62 | 0.180 |
Why?
|
| Ribosomal Proteins | 1 | 2020 | 70 | 0.180 |
Why?
|
| Medical Order Entry Systems | 1 | 2020 | 41 | 0.180 |
Why?
|
| Joints | 6 | 2013 | 84 | 0.180 |
Why?
|
| Glycoproteins | 1 | 2002 | 311 | 0.180 |
Why?
|
| Risk Assessment | 7 | 2020 | 2992 | 0.180 |
Why?
|
| CD40 Antigens | 1 | 2020 | 80 | 0.180 |
Why?
|
| Prognosis | 10 | 2016 | 3344 | 0.180 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 273 | 0.180 |
Why?
|
| Arthritis, Infectious | 2 | 1991 | 50 | 0.170 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2020 | 53 | 0.170 |
Why?
|
| Tracheobronchomalacia | 1 | 2019 | 14 | 0.170 |
Why?
|
| Antigen-Antibody Complex | 1 | 2020 | 88 | 0.170 |
Why?
|
| Cell Adhesion Molecules | 2 | 2018 | 169 | 0.170 |
Why?
|
| Laryngostenosis | 1 | 2019 | 20 | 0.170 |
Why?
|
| Lipoproteins, HDL | 2 | 2017 | 76 | 0.170 |
Why?
|
| Chemokine CCL2 | 1 | 2020 | 105 | 0.170 |
Why?
|
| Catastrophization | 1 | 2019 | 8 | 0.170 |
Why?
|
| Tracheal Stenosis | 1 | 2019 | 24 | 0.170 |
Why?
|
| Pneumococcal Vaccines | 1 | 2020 | 132 | 0.170 |
Why?
|
| Disease Progression | 13 | 2020 | 2423 | 0.170 |
Why?
|
| Systemic Vasculitis | 1 | 2019 | 2 | 0.170 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 174 | 0.170 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2019 | 9 | 0.160 |
Why?
|
| Knee Joint | 4 | 2009 | 325 | 0.160 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 351 | 0.160 |
Why?
|
| Surveys and Questionnaires | 16 | 2017 | 4673 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 548 | 0.160 |
Why?
|
| Sialoglycoproteins | 3 | 2004 | 158 | 0.160 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2020 | 90 | 0.160 |
Why?
|
| Eosinophilic Granuloma | 1 | 2018 | 3 | 0.160 |
Why?
|
| Prevalence | 5 | 2020 | 2270 | 0.160 |
Why?
|
| Harm Reduction | 1 | 2019 | 24 | 0.160 |
Why?
|
| Metagenomics | 1 | 2019 | 131 | 0.160 |
Why?
|
| Interleukin-10 | 1 | 2021 | 304 | 0.160 |
Why?
|
| Immunotherapy, Active | 1 | 1998 | 8 | 0.160 |
Why?
|
| Contraception Behavior | 1 | 2019 | 80 | 0.160 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1998 | 72 | 0.160 |
Why?
|
| Contraceptive Agents, Female | 1 | 2019 | 65 | 0.160 |
Why?
|
| Axillary Artery | 1 | 2018 | 12 | 0.160 |
Why?
|
| Adolescent | 18 | 2023 | 17935 | 0.160 |
Why?
|
| Animals | 14 | 2019 | 32158 | 0.160 |
Why?
|
| Collagen | 2 | 1991 | 415 | 0.160 |
Why?
|
| Central Nervous System Sensitization | 1 | 2018 | 3 | 0.160 |
Why?
|
| 14-3-3 Proteins | 1 | 2017 | 13 | 0.150 |
Why?
|
| Vascular Diseases | 1 | 2020 | 230 | 0.150 |
Why?
|
| Pain Threshold | 1 | 2018 | 67 | 0.150 |
Why?
|
| Chemokines | 1 | 2019 | 214 | 0.150 |
Why?
|
| Immunoglobulin A | 2 | 2017 | 173 | 0.150 |
Why?
|
| Antibody Formation | 4 | 2006 | 274 | 0.150 |
Why?
|
| Scleroderma, Diffuse | 2 | 2008 | 4 | 0.150 |
Why?
|
| Skin Diseases | 2 | 1990 | 124 | 0.150 |
Why?
|
| Neutrophils | 4 | 2023 | 1171 | 0.150 |
Why?
|
| Pain Perception | 1 | 2018 | 37 | 0.150 |
Why?
|
| Arthralgia | 1 | 2018 | 50 | 0.150 |
Why?
|
| Quality of Life | 11 | 2019 | 2390 | 0.150 |
Why?
|
| Health Care Costs | 2 | 2016 | 384 | 0.150 |
Why?
|
| Comorbidity | 4 | 2017 | 1476 | 0.150 |
Why?
|
| Reproductive Health | 1 | 2018 | 69 | 0.150 |
Why?
|
| Crowdsourcing | 2 | 2016 | 16 | 0.140 |
Why?
|
| International Cooperation | 5 | 2010 | 175 | 0.140 |
Why?
|
| Receptors, CXCR5 | 1 | 2016 | 11 | 0.140 |
Why?
|
| Interleukin-13 | 1 | 2017 | 132 | 0.140 |
Why?
|
| Family Planning Services | 1 | 2018 | 67 | 0.140 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2017 | 46 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2023 | 503 | 0.140 |
Why?
|
| Cross-Sectional Studies | 9 | 2019 | 4447 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 124 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1088 | 0.140 |
Why?
|
| HLA-DP beta-Chains | 1 | 2017 | 76 | 0.140 |
Why?
|
| Autoimmune Diseases | 2 | 2007 | 396 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 1998 | 631 | 0.140 |
Why?
|
| Doxycycline | 3 | 2005 | 56 | 0.140 |
Why?
|
| Th17 Cells | 1 | 2016 | 58 | 0.140 |
Why?
|
| Odds Ratio | 6 | 2018 | 968 | 0.140 |
Why?
|
| Antibodies | 5 | 2010 | 374 | 0.140 |
Why?
|
| Electronic Health Records | 2 | 2020 | 805 | 0.140 |
Why?
|
| Perioperative Care | 1 | 1997 | 127 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2013 | 54 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 449 | 0.140 |
Why?
|
| Rare Diseases | 1 | 2017 | 90 | 0.140 |
Why?
|
| Uric Acid | 2 | 2008 | 150 | 0.130 |
Why?
|
| Morbidity | 1 | 2017 | 278 | 0.130 |
Why?
|
| Vaccines, Synthetic | 1 | 1996 | 124 | 0.130 |
Why?
|
| Health Status Indicators | 3 | 2006 | 155 | 0.130 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2004 | 222 | 0.130 |
Why?
|
| Seroepidemiologic Studies | 2 | 2014 | 141 | 0.130 |
Why?
|
| Immunoassay | 1 | 2016 | 97 | 0.130 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2017 | 110 | 0.130 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 2365 | 0.130 |
Why?
|
| Glucocorticoids | 1 | 2020 | 551 | 0.130 |
Why?
|
| Aorta, Thoracic | 1 | 2018 | 246 | 0.130 |
Why?
|
| Certolizumab Pegol | 2 | 2016 | 3 | 0.130 |
Why?
|
| Receptors, Interleukin-1 | 4 | 2004 | 227 | 0.130 |
Why?
|
| Hand | 3 | 2010 | 135 | 0.130 |
Why?
|
| Interferon-beta | 1 | 2015 | 80 | 0.130 |
Why?
|
| Genes, MHC Class II | 1 | 2015 | 69 | 0.120 |
Why?
|
| Counseling | 1 | 2018 | 346 | 0.120 |
Why?
|
| Orthopedic Procedures | 1 | 1997 | 213 | 0.120 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 2807 | 0.120 |
Why?
|
| Herpes Zoster | 2 | 2016 | 333 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 89 | 0.120 |
Why?
|
| Spondylitis, Ankylosing | 2 | 1992 | 43 | 0.120 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 1317 | 0.120 |
Why?
|
| Hypercholesterolemia | 1 | 2015 | 92 | 0.120 |
Why?
|
| Virus Diseases | 3 | 2007 | 200 | 0.120 |
Why?
|
| Global Health | 1 | 2017 | 290 | 0.120 |
Why?
|
| Algorithms | 5 | 2010 | 1494 | 0.120 |
Why?
|
| Early Diagnosis | 3 | 2010 | 220 | 0.120 |
Why?
|
| Young Adult | 9 | 2023 | 10508 | 0.120 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1996 | 154 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 1996 | 211 | 0.120 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2016 | 159 | 0.120 |
Why?
|
| Disease Management | 1 | 2018 | 563 | 0.120 |
Why?
|
| Leukocytes | 3 | 2019 | 284 | 0.120 |
Why?
|
| Cholesterol | 1 | 2016 | 368 | 0.120 |
Why?
|
| Lysophospholipase | 1 | 2014 | 11 | 0.120 |
Why?
|
| Antibodies, Antinuclear | 1 | 2014 | 60 | 0.120 |
Why?
|
| Consanguinity | 1 | 2014 | 49 | 0.120 |
Why?
|
| Multifactorial Inheritance | 1 | 2015 | 128 | 0.120 |
Why?
|
| Genetic Variation | 3 | 2015 | 893 | 0.120 |
Why?
|
| Survival Rate | 2 | 2017 | 1649 | 0.110 |
Why?
|
| Urban Population | 1 | 1996 | 405 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1405 | 0.110 |
Why?
|
| Transcriptome | 1 | 2019 | 742 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2021 | 4527 | 0.110 |
Why?
|
| Recurrence | 3 | 2023 | 950 | 0.110 |
Why?
|
| Interleukin-1 | 1 | 1998 | 971 | 0.110 |
Why?
|
| Rheumatoid Nodule | 2 | 2010 | 6 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 431 | 0.110 |
Why?
|
| Complementary Therapies | 1 | 2014 | 73 | 0.110 |
Why?
|
| Metacarpophalangeal Joint | 2 | 2003 | 11 | 0.110 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 26 | 0.110 |
Why?
|
| Wrist Joint | 2 | 2010 | 59 | 0.110 |
Why?
|
| Models, Genetic | 2 | 2013 | 579 | 0.110 |
Why?
|
| Chimera | 1 | 1993 | 59 | 0.110 |
Why?
|
| Adipokines | 2 | 2024 | 43 | 0.110 |
Why?
|
| Genotype | 7 | 2015 | 1830 | 0.110 |
Why?
|
| Arthroscopy | 3 | 2005 | 200 | 0.110 |
Why?
|
| Gene Expression | 4 | 2022 | 1442 | 0.110 |
Why?
|
| Macrophages | 1 | 2020 | 1282 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2013 | 124 | 0.110 |
Why?
|
| North America | 4 | 2020 | 263 | 0.110 |
Why?
|
| Clinical Protocols | 3 | 2010 | 234 | 0.110 |
Why?
|
| Rheumatic Fever | 1 | 1992 | 8 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 688 | 0.110 |
Why?
|
| Cholesterol, HDL | 1 | 2013 | 185 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1550 | 0.100 |
Why?
|
| Internet | 1 | 2017 | 601 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2014 | 207 | 0.100 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2012 | 5 | 0.100 |
Why?
|
| Cotinine | 1 | 2012 | 69 | 0.100 |
Why?
|
| Calcium Carbonate | 1 | 2011 | 8 | 0.100 |
Why?
|
| Monocytes | 4 | 2019 | 504 | 0.100 |
Why?
|
| Mortality | 1 | 2014 | 290 | 0.100 |
Why?
|
| Pilot Projects | 5 | 2003 | 1379 | 0.100 |
Why?
|
| Bone Density | 3 | 2010 | 432 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2015 | 332 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2015 | 677 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 309 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 1999 | 783 | 0.100 |
Why?
|
| Colchicine | 1 | 1991 | 24 | 0.100 |
Why?
|
| Vitamin D | 2 | 2011 | 341 | 0.100 |
Why?
|
| Bone and Bones | 2 | 2000 | 283 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2015 | 3072 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 289 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 446 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 1001 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 348 | 0.090 |
Why?
|
| RANK Ligand | 1 | 2010 | 26 | 0.090 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2010 | 35 | 0.090 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2010 | 15 | 0.090 |
Why?
|
| STAT4 Transcription Factor | 1 | 2010 | 4 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 1995 | 685 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 1992 | 222 | 0.090 |
Why?
|
| Leukocyte Common Antigens | 1 | 2010 | 75 | 0.090 |
Why?
|
| Logistic Models | 8 | 2014 | 1863 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 5 | 2003 | 184 | 0.090 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1992 | 609 | 0.090 |
Why?
|
| Chlorambucil | 1 | 1989 | 8 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 1992 | 447 | 0.090 |
Why?
|
| Hypertension | 2 | 2015 | 1065 | 0.090 |
Why?
|
| Acacia | 1 | 2009 | 1 | 0.090 |
Why?
|
| Scutellaria baicalensis | 1 | 2009 | 1 | 0.090 |
Why?
|
| Fractures, Spontaneous | 1 | 2009 | 14 | 0.090 |
Why?
|
| Computational Biology | 3 | 2020 | 540 | 0.090 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2009 | 20 | 0.090 |
Why?
|
| Genes, rel | 1 | 2009 | 4 | 0.090 |
Why?
|
| Pulmonary Fibrosis | 1 | 1992 | 331 | 0.080 |
Why?
|
| Isoxazoles | 2 | 1999 | 56 | 0.080 |
Why?
|
| Exercise Therapy | 2 | 2023 | 353 | 0.080 |
Why?
|
| Flavonoids | 1 | 2009 | 68 | 0.080 |
Why?
|
| Reference Values | 3 | 2006 | 745 | 0.080 |
Why?
|
| Societies, Medical | 5 | 2012 | 685 | 0.080 |
Why?
|
| Phagocytes | 1 | 1989 | 91 | 0.080 |
Why?
|
| Immunoglobulins | 2 | 2002 | 148 | 0.080 |
Why?
|
| Age Distribution | 2 | 2015 | 341 | 0.080 |
Why?
|
| MEDLINE | 1 | 2008 | 22 | 0.080 |
Why?
|
| Cluster Analysis | 2 | 2020 | 466 | 0.080 |
Why?
|
| Urate Oxidase | 1 | 2008 | 9 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2006 | 510 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2009 | 164 | 0.080 |
Why?
|
| Cartilage, Articular | 2 | 2005 | 291 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 25 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2009 | 275 | 0.080 |
Why?
|
| Health Behavior | 1 | 2014 | 704 | 0.080 |
Why?
|
| Lymphotoxin-alpha | 2 | 2004 | 9 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 1998 | 34 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2004 | 524 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2011 | 460 | 0.080 |
Why?
|
| Renal Circulation | 1 | 1988 | 54 | 0.080 |
Why?
|
| Eye Diseases | 4 | 2018 | 76 | 0.080 |
Why?
|
| Canada | 2 | 2020 | 337 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2009 | 159 | 0.080 |
Why?
|
| Plant Extracts | 1 | 2009 | 153 | 0.080 |
Why?
|
| Aneurysm | 1 | 1988 | 29 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 301 | 0.070 |
Why?
|
| Collagen Type I | 1 | 2008 | 110 | 0.070 |
Why?
|
| Injections, Intravenous | 3 | 2003 | 204 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 653 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 905 | 0.070 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 1998 | 25 | 0.070 |
Why?
|
| Bone Diseases | 1 | 1988 | 58 | 0.070 |
Why?
|
| Muscular Diseases | 1 | 1988 | 104 | 0.070 |
Why?
|
| NF-kappa B | 2 | 2021 | 639 | 0.070 |
Why?
|
| Immunocompetence | 1 | 2007 | 41 | 0.070 |
Why?
|
| CTLA-4 Antigen | 2 | 2009 | 78 | 0.070 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2006 | 32 | 0.070 |
Why?
|
| Retrospective Studies | 10 | 2023 | 12615 | 0.070 |
Why?
|
| Acute-Phase Reaction | 3 | 2010 | 39 | 0.070 |
Why?
|
| Risk | 2 | 2006 | 829 | 0.070 |
Why?
|
| Synovitis | 3 | 2010 | 24 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2007 | 164 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 374 | 0.070 |
Why?
|
| Glucosamine | 1 | 2006 | 12 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 1725 | 0.070 |
Why?
|
| Febuxostat | 1 | 2005 | 1 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 1998 | 257 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 1130 | 0.070 |
Why?
|
| Probenecid | 1 | 2005 | 7 | 0.070 |
Why?
|
| Diet | 2 | 2023 | 1074 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2003 | 20 | 0.070 |
Why?
|
| Chondroitin Sulfates | 1 | 2006 | 33 | 0.070 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2006 | 34 | 0.070 |
Why?
|
| Tuberculin Test | 1 | 2006 | 32 | 0.070 |
Why?
|
| Allopurinol | 1 | 2005 | 55 | 0.070 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 59 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 2 | 2004 | 206 | 0.070 |
Why?
|
| Asthma | 1 | 2019 | 2150 | 0.070 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 234 | 0.060 |
Why?
|
| Southeastern United States | 2 | 2016 | 30 | 0.060 |
Why?
|
| Haplotypes | 3 | 2017 | 475 | 0.060 |
Why?
|
| Europe | 3 | 2010 | 343 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 1193 | 0.060 |
Why?
|
| Terminology as Topic | 3 | 2010 | 186 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 2 | 2003 | 165 | 0.060 |
Why?
|
| Autoantigens | 2 | 2017 | 399 | 0.060 |
Why?
|
| Phenotype | 3 | 2023 | 2859 | 0.060 |
Why?
|
| Alabama | 2 | 1996 | 28 | 0.060 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2005 | 53 | 0.060 |
Why?
|
| Isoenzymes | 2 | 2003 | 287 | 0.060 |
Why?
|
| Research Design | 3 | 2004 | 949 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 796 | 0.060 |
Why?
|
| Extracellular Matrix | 2 | 2003 | 439 | 0.060 |
Why?
|
| Prednisone | 3 | 2017 | 232 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2009 | 332 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 1998 | 675 | 0.060 |
Why?
|
| HLA-B27 Antigen | 2 | 1996 | 11 | 0.060 |
Why?
|
| Dehydroepiandrosterone | 1 | 2004 | 49 | 0.060 |
Why?
|
| Injections, Intra-Articular | 2 | 2003 | 45 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2005 | 3587 | 0.060 |
Why?
|
| Fluoroscopy | 1 | 2004 | 141 | 0.060 |
Why?
|
| Obesity | 3 | 2024 | 2523 | 0.060 |
Why?
|
| Half-Life | 2 | 2003 | 145 | 0.060 |
Why?
|
| Laryngoscopy | 1 | 2004 | 92 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2006 | 192 | 0.060 |
Why?
|
| Drug Utilization Review | 1 | 2003 | 57 | 0.060 |
Why?
|
| Thinness | 1 | 2024 | 87 | 0.060 |
Why?
|
| Metatarsophalangeal Joint | 1 | 2003 | 33 | 0.060 |
Why?
|
| Platelet Activation | 1 | 2023 | 68 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2004 | 136 | 0.050 |
Why?
|
| Drug Resistance | 3 | 2012 | 162 | 0.050 |
Why?
|
| Biological Therapy | 1 | 2003 | 26 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 1443 | 0.050 |
Why?
|
| Patient Dropouts | 2 | 2002 | 65 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 225 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 218 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 337 | 0.050 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2002 | 17 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2004 | 255 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2003 | 167 | 0.050 |
Why?
|
| Lectins | 1 | 2002 | 47 | 0.050 |
Why?
|
| Chloroquine | 1 | 2002 | 52 | 0.050 |
Why?
|
| Drugs, Investigational | 1 | 2002 | 30 | 0.050 |
Why?
|
| Placebos | 3 | 2009 | 198 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2003 | 669 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2022 | 94 | 0.050 |
Why?
|
| Integrins | 1 | 2002 | 79 | 0.050 |
Why?
|
| Skin | 5 | 2009 | 668 | 0.050 |
Why?
|
| Child | 4 | 2023 | 18537 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2002 | 143 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2022 | 324 | 0.050 |
Why?
|
| Cartilage | 1 | 2003 | 182 | 0.050 |
Why?
|
| Quality Improvement | 2 | 2020 | 958 | 0.050 |
Why?
|
| Range of Motion, Articular | 1 | 2003 | 354 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2002 | 273 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2003 | 211 | 0.050 |
Why?
|
| Drug Evaluation | 2 | 1999 | 79 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 58 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2001 | 47 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2001 | 84 | 0.050 |
Why?
|
| Skinfold Thickness | 1 | 2000 | 48 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2020 | 60 | 0.050 |
Why?
|
| Lymphocyte Count | 2 | 2000 | 133 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2019 | 2404 | 0.050 |
Why?
|
| HLA-DR4 Antigen | 1 | 2000 | 76 | 0.050 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2000 | 7 | 0.040 |
Why?
|
| Complement Activation | 1 | 2023 | 343 | 0.040 |
Why?
|
| Mesenteric Arteries | 1 | 2020 | 16 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2019 | 750 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 56 | 0.040 |
Why?
|
| Antibody Diversity | 1 | 2020 | 16 | 0.040 |
Why?
|
| Injections, Intramuscular | 2 | 2000 | 118 | 0.040 |
Why?
|
| Safety | 3 | 2002 | 298 | 0.040 |
Why?
|
| Aorta, Abdominal | 1 | 2020 | 39 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1359 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2020 | 260 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2001 | 200 | 0.040 |
Why?
|
| Overweight | 1 | 2024 | 468 | 0.040 |
Why?
|
| India | 1 | 2020 | 135 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2581 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2000 | 73 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2003 | 409 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2019 | 58 | 0.040 |
Why?
|
| Urinalysis | 1 | 2020 | 62 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 303 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 480 | 0.040 |
Why?
|
| Bronchial Diseases | 1 | 2019 | 38 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2019 | 23 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2003 | 1033 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2003 | 1127 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2021 | 198 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 147 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2023 | 617 | 0.040 |
Why?
|
| Adiposity | 1 | 2024 | 468 | 0.040 |
Why?
|
| Social Participation | 1 | 2019 | 13 | 0.040 |
Why?
|
| Family Practice | 1 | 2003 | 428 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2022 | 288 | 0.040 |
Why?
|
| Muscle Relaxants, Central | 1 | 1999 | 9 | 0.040 |
Why?
|
| Freund's Adjuvant | 1 | 1998 | 17 | 0.040 |
Why?
|
| RNA Interference | 1 | 2020 | 438 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 1996 | 82 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2020 | 165 | 0.040 |
Why?
|
| Age Factors | 4 | 2009 | 2911 | 0.040 |
Why?
|
| Arteries | 1 | 2020 | 250 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 223 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 545 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2000 | 248 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2003 | 352 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2021 | 383 | 0.040 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2018 | 10 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 3 | 2004 | 254 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 138 | 0.040 |
Why?
|
| Hospitals, University | 2 | 2002 | 172 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 1999 | 299 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 737 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 358 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2017 | 25 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 181 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 352 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2018 | 93 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 416 | 0.040 |
Why?
|
| Symptom Flare Up | 1 | 2017 | 40 | 0.040 |
Why?
|
| T-Box Domain Proteins | 1 | 2017 | 93 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 1999 | 195 | 0.040 |
Why?
|
| HLA-DP Antigens | 1 | 2017 | 32 | 0.040 |
Why?
|
| Cell Line | 2 | 2020 | 2657 | 0.040 |
Why?
|
| Cytosol | 1 | 2017 | 209 | 0.040 |
Why?
|
| Forecasting | 2 | 2003 | 332 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2017 | 180 | 0.040 |
Why?
|
| Intermittent Claudication | 1 | 2018 | 108 | 0.040 |
Why?
|
| Absorptiometry, Photon | 2 | 2009 | 221 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 383 | 0.040 |
Why?
|
| Fibroblasts | 2 | 2019 | 838 | 0.040 |
Why?
|
| Mass Screening | 1 | 2003 | 1024 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2021 | 1562 | 0.030 |
Why?
|
| Chlamydia trachomatis | 1 | 1996 | 36 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2016 | 103 | 0.030 |
Why?
|
| Markov Chains | 1 | 2016 | 115 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 209 | 0.030 |
Why?
|
| Subtraction Technique | 2 | 1993 | 27 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2003 | 1182 | 0.030 |
Why?
|
| Peptides | 2 | 2006 | 864 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 1998 | 2003 | 0.030 |
Why?
|
| Mice | 3 | 2013 | 15085 | 0.030 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 1995 | 5 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 1996 | 65 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 129 | 0.030 |
Why?
|
| Gonorrhea | 1 | 1996 | 54 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 1995 | 78 | 0.030 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2015 | 14 | 0.030 |
Why?
|
| Fibrosis | 1 | 2017 | 458 | 0.030 |
Why?
|
| Dextrans | 1 | 1995 | 74 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1918 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1998 | 2796 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 1996 | 184 | 0.030 |
Why?
|
| Analgesics | 1 | 1996 | 157 | 0.030 |
Why?
|
| Low Back Pain | 1 | 1996 | 95 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2017 | 824 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 1996 | 345 | 0.030 |
Why?
|
| Femur | 2 | 2005 | 194 | 0.030 |
Why?
|
| Alveolar Bone Loss | 1 | 1993 | 10 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2013 | 14 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 72 | 0.030 |
Why?
|
| Tibia | 2 | 2005 | 172 | 0.030 |
Why?
|
| Stomach Ulcer | 1 | 1993 | 9 | 0.030 |
Why?
|
| Duodenal Ulcer | 1 | 1993 | 10 | 0.030 |
Why?
|
| Lymphocytes | 1 | 1995 | 342 | 0.030 |
Why?
|
| Misoprostol | 1 | 1993 | 18 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 467 | 0.030 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2013 | 3 | 0.030 |
Why?
|
| Virion | 1 | 1993 | 74 | 0.030 |
Why?
|
| Therapeutic Irrigation | 2 | 2005 | 67 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2019 | 823 | 0.030 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2013 | 6 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 1993 | 409 | 0.030 |
Why?
|
| Bone Resorption | 1 | 1993 | 74 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 1996 | 269 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 163 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 1995 | 196 | 0.030 |
Why?
|
| Flurbiprofen | 1 | 1992 | 3 | 0.030 |
Why?
|
| Exons | 1 | 2014 | 303 | 0.030 |
Why?
|
| Autoradiography | 1 | 1992 | 71 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 1992 | 45 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 58 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 1993 | 79 | 0.030 |
Why?
|
| Exome | 1 | 2014 | 206 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1992 | 194 | 0.030 |
Why?
|
| Pedigree | 1 | 2014 | 474 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 1993 | 115 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 501 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1992 | 170 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2011 | 612 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2013 | 126 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 1993 | 152 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 1992 | 58 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 280 | 0.030 |
Why?
|
| Epoxide Hydrolases | 1 | 2012 | 10 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1992 | 79 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1993 | 169 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2013 | 185 | 0.030 |
Why?
|
| Communication | 1 | 2018 | 749 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 135 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2013 | 121 | 0.030 |
Why?
|
| Growth Substances | 1 | 1992 | 136 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 1995 | 371 | 0.030 |
Why?
|
| Cognition | 1 | 2019 | 980 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1088 | 0.020 |
Why?
|
| Parvoviridae Infections | 1 | 1991 | 11 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1991 | 163 | 0.020 |
Why?
|
| Oncogenes | 1 | 1992 | 104 | 0.020 |
Why?
|
| Cadaver | 1 | 1992 | 316 | 0.020 |
Why?
|
| Laminin | 1 | 1991 | 69 | 0.020 |
Why?
|
| Anticoagulants | 1 | 1995 | 549 | 0.020 |
Why?
|
| Sjogren's Syndrome | 1 | 1991 | 42 | 0.020 |
Why?
|
| Receptors, CCR6 | 1 | 2010 | 3 | 0.020 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2010 | 11 | 0.020 |
Why?
|
| Area Under Curve | 2 | 2003 | 277 | 0.020 |
Why?
|
| SOXD Transcription Factors | 1 | 2010 | 5 | 0.020 |
Why?
|
| Mycobacterium Infections | 1 | 1991 | 61 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 1137 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 682 | 0.020 |
Why?
|
| Clinical Chemistry Tests | 1 | 2010 | 9 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 1991 | 123 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 313 | 0.020 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2010 | 18 | 0.020 |
Why?
|
| Immunity, Cellular | 2 | 2007 | 263 | 0.020 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 1991 | 76 | 0.020 |
Why?
|
| Hand Joints | 1 | 2010 | 5 | 0.020 |
Why?
|
| Technology, Radiologic | 1 | 1990 | 6 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 960 | 0.020 |
Why?
|
| Foot Joints | 1 | 2010 | 6 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1993 | 340 | 0.020 |
Why?
|
| Arthrography | 2 | 2000 | 22 | 0.020 |
Why?
|
| Herpesviridae Infections | 1 | 1991 | 138 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 2121 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 211 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1992 | 1153 | 0.020 |
Why?
|
| Plant Bark | 1 | 2009 | 11 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 221 | 0.020 |
Why?
|
| Plant Roots | 1 | 2009 | 36 | 0.020 |
Why?
|
| Herpesvirus 2, Human | 1 | 2009 | 28 | 0.020 |
Why?
|
| Optic Atrophy | 1 | 1989 | 10 | 0.020 |
Why?
|
| Meningitis, Aseptic | 1 | 1989 | 15 | 0.020 |
Why?
|
| Foot | 1 | 2010 | 104 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 1989 | 193 | 0.020 |
Why?
|
| Infusions, Subcutaneous | 1 | 2009 | 19 | 0.020 |
Why?
|
| Femur Neck | 1 | 2009 | 60 | 0.020 |
Why?
|
| Immobilization | 1 | 1989 | 44 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 455 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2009 | 81 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2008 | 69 | 0.020 |
Why?
|
| Drug Eruptions | 2 | 2000 | 26 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 487 | 0.020 |
Why?
|
| Viruses | 1 | 1989 | 94 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2009 | 279 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 389 | 0.020 |
Why?
|
| Genomics | 1 | 2013 | 653 | 0.020 |
Why?
|
| Consensus | 1 | 2010 | 531 | 0.020 |
Why?
|
| Leukocytosis | 1 | 1988 | 35 | 0.020 |
Why?
|
| Meningitis | 1 | 1989 | 74 | 0.020 |
Why?
|
| Electromyography | 1 | 1989 | 325 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 771 | 0.020 |
Why?
|
| Hematoma | 1 | 1988 | 51 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2009 | 217 | 0.020 |
Why?
|
| Patient Participation | 1 | 1991 | 362 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 2608 | 0.020 |
Why?
|
| Seasons | 1 | 2009 | 450 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 431 | 0.020 |
Why?
|
| Necrosis | 1 | 1988 | 211 | 0.020 |
Why?
|
| Syndrome | 1 | 1988 | 339 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 1103 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 353 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 613 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2009 | 159 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2007 | 69 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 1974 | 0.020 |
Why?
|
| Citrulline | 1 | 2006 | 39 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 685 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 595 | 0.020 |
Why?
|
| Celecoxib | 1 | 2006 | 38 | 0.020 |
Why?
|
| Blood Vessels | 1 | 1988 | 181 | 0.020 |
Why?
|
| Pregnancy | 1 | 2018 | 5555 | 0.020 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2005 | 4 | 0.020 |
Why?
|
| Child, Preschool | 1 | 1999 | 9164 | 0.020 |
Why?
|
| Cattle | 1 | 2008 | 935 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 121 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2007 | 197 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 2007 | 130 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2007 | 135 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1995 | 2164 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2006 | 112 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2004 | 66 | 0.020 |
Why?
|
| Retreatment | 1 | 2004 | 70 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2006 | 506 | 0.010 |
Why?
|
| Rats | 1 | 1992 | 5035 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2009 | 651 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 1318 | 0.010 |
Why?
|
| Exercise | 1 | 2014 | 1611 | 0.010 |
Why?
|
| Epidemiological Monitoring | 1 | 2003 | 47 | 0.010 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2003 | 69 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 3371 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2003 | 15 | 0.010 |
Why?
|
| Professional Practice | 1 | 2003 | 63 | 0.010 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2003 | 22 | 0.010 |
Why?
|
| Collagenases | 1 | 2003 | 22 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 55 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2006 | 362 | 0.010 |
Why?
|
| Vision Disorders | 1 | 2003 | 130 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2006 | 447 | 0.010 |
Why?
|
| Prednisolone | 1 | 2002 | 77 | 0.010 |
Why?
|
| Hospitals, Community | 1 | 2002 | 47 | 0.010 |
Why?
|
| Environmental Monitoring | 1 | 2003 | 260 | 0.010 |
Why?
|
| Literature | 1 | 2001 | 2 | 0.010 |
Why?
|
| Liver | 1 | 1989 | 1693 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 249 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2001 | 32 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2007 | 735 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 633 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2003 | 241 | 0.010 |
Why?
|
| Demography | 1 | 2001 | 264 | 0.010 |
Why?
|
| Crystallization | 1 | 2000 | 138 | 0.010 |
Why?
|
| Menorrhagia | 1 | 2000 | 14 | 0.010 |
Why?
|
| Immunization, Secondary | 1 | 2000 | 82 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2000 | 136 | 0.010 |
Why?
|
| Transaminases | 1 | 1999 | 25 | 0.010 |
Why?
|
| Exanthema | 1 | 2000 | 77 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1999 | 72 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2001 | 247 | 0.010 |
Why?
|
| Naproxen | 1 | 1999 | 11 | 0.010 |
Why?
|
| Body Temperature | 1 | 2000 | 211 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 924 | 0.010 |
Why?
|
| Anemia | 1 | 2000 | 144 | 0.010 |
Why?
|
| Hemoglobinometry | 1 | 1998 | 1 | 0.010 |
Why?
|
| Linear Models | 1 | 2000 | 777 | 0.010 |
Why?
|
| Pathology | 1 | 1998 | 21 | 0.010 |
Why?
|
| Health Surveys | 1 | 1999 | 447 | 0.010 |
Why?
|
| Observer Variation | 1 | 1998 | 298 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2000 | 1227 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 1998 | 119 | 0.010 |
Why?
|
| Extracorporeal Circulation | 1 | 1995 | 14 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 178 | 0.010 |
Why?
|
| Platelet Count | 1 | 1995 | 83 | 0.010 |
Why?
|
| Hemofiltration | 1 | 1995 | 31 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1995 | 331 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1995 | 324 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1993 | 44 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1995 | 221 | 0.010 |
Why?
|
| Dura Mater | 1 | 1989 | 29 | 0.010 |
Why?
|
| Peritonitis | 1 | 1989 | 76 | 0.010 |
Why?
|
| Craniotomy | 1 | 1989 | 67 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1993 | 1598 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1993 | 3914 | 0.000 |
Why?
|
| Biopsy | 1 | 1989 | 1056 | 0.000 |
Why?
|